The lives of about 400 women with early breast cancer could be saved every year if bisphosphonates were routinely used as adjuvant therapy to prevent recurrence, oncologists say. But the recommended drugs such as zoledronate are off-patent, unlicensed and currently underused for the prevention of breast cancer recurrence, the MOGA 2019 ASM in Canberra was ...
Bisphosphonates could save the lives of hundreds of women with breast cancer
By Michael Woodhead
21 Aug 2019